Tg Therapeutics (TGTX) Total Current Liabilities (2010 - 2026)

Tg Therapeutics' Total Current Liabilities history runs 17 years deep, the most recent figure standing at $187.1 million for Q1 2026.

• On a quarterly basis, Total Current Liabilities rose 16.79% year-over-year to $187.1 million in Q1 2026; TTM through Mar 2026 was $187.1 million, a 16.79% increase from a year earlier, with the FY2025 full-year figure at $153.8 million, up 69.57% from the prior year.
• Total Current Liabilities advanced to $187.1 million in Q1 2026 per TGTX's latest filing, from $153.8 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $187.1 million in Q1 2026 and bottomed at $36.4 million in Q3 2022.
• The 5-year median for Total Current Liabilities is $90.7 million (2024), against an average of $99.3 million.
• Across the five-year window, Total Current Liabilities tumbled 58.42% in 2022 and jumped 116.92% in 2024, its largest moves.
• Year by year, Total Current Liabilities stood at $53.2 million in 2022, then climbed by 0.98% to $53.7 million in 2023, then surged by 68.8% to $90.7 million in 2024, then jumped by 69.57% to $153.8 million in 2025, then increased by 21.69% to $187.1 million in 2026.
• Per Business Quant, the three latest TGTX Total Current Liabilities figures stand at $187.1 million (Q1 2026), $153.8 million (Q4 2025), and $156.8 million (Q3 2025).